This article is more than 5 years old. Information may no longer be current.

Gemini Therapeutics closes $42.5 million in financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Gemini Therapeutics has completed $42.5 million in Series A financing, according to a company press release.

Co-led by Atlas Venture, Lightstone Ventures and OrbiMed, the financing is to advance multiple programs to the clinical stage, including those focused on genetically defined dry age-related macular degeneration, the release said.

“We believe the time is right to harness genetic insights into AMD, and we’ve gathered the people, the technology and the resources necessary to lead the translational effort,” James McLaughlin, Gemini CEO, president and co-founder, said in the release.